|Systematic (IUPAC) name|
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
|Biological half-life||8.6 hours|
|ATC code||C08CA04 (WHO)|
|Molar mass||479.525 g/mol[[Script error: No such module "String".]]|
|Melting point||6 °C (43 °F)|
Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Furthermore, nicardipine does not intrinsically decrease myocardial contractility and may be useful in the management of congestive heart failure. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.
Nicardipine must be used with caution in patients with renal failure because of possible kidney shutdown.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
Nicardipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal models, nicardipine produced relaxation of coronary vascular smooth muscle at drug levels which cause little or no negative inotropic effect.
|30px||This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.|
- Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.